Attached files

file filename
EX-99.1 - PRESS RELEASE - Cascadian Therapeutics, Inc.d370243dex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2012

 

 

ONCOTHYREON INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33882   26-0868560
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
 

(IRS Employer

Identification No.)

   

2601 Fourth Avenue, Suite 500

Seattle, Washington 98121

(Address of principal executive offices, including zip code)

(206) 801-2100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On June 21, 2012, Oncothyreon Inc. (the “Company”) announced the appointment of Dr. Scott Peterson as the Company’s Chief Scientific Officer, effective immediately. Dr. Peterson has served as the Company’s Vice President, Research and Development since August 2009.

In connection with Dr. Peterson’s appointment as Chief Scientific Officer, the compensation committee of the Company’s board of directors approved an increase to Dr. Peterson’s annual base salary to $255,000, effective June 15, 2012.

A copy of the press release of the Company announcing Dr. Peterson’s appointment is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

  

Description

99.1    Press Release issued by Oncothyreon Inc. dated June 21, 2012.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ONCOTHYREON INC.
By:  

/s/ Robert L. Kirkman, M.D.

  Robert L. Kirkman, M.D.
  President & Chief Executive Officer

Date: June 21, 2012


EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1    Press Release issued by Oncothyreon Inc. dated June 21, 2012.